All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @alekosmos88 on TikTok · 57s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @alekosmos88's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00And then we had about fifteen years ago,
  2. 0:03we had everything to do from there,
  3. 0:07we had all the ability to go to a local program.
  4. 0:11And many people could't trust them with their own existence.
  5. 0:18So there was an interesting number of questions
  6. 0:23I felt at the very moment that we didn't know
  7. 0:27And if you don't know, we can't be able to make it.
  8. 0:31In the future, we have a lot to do with it.
  9. 0:33We're not just going to do it, we're just going to do it.
  10. 0:35The first time I've decided to do this, I want to make it easier.
  11. 0:39To be honest, we're not going to be asking for anything from the beginning.
  12. 0:43I'm going to make a new version of this version of Brace and Lactuña.
  13. 0:47We'll be able to make it more as a new version for the beginning.
  14. 0:53And if I ask you to make it, it's too much.
  15. 0:56I'm new, I love you now.

@alekosmos88's Wegovy progress claim, fact-checked

Alekosmos88

TikTok creator

22.1K viewsWatch on TikTok

Quick answer

The creator reports 8.1 kg of weight loss over five weeks on Wegovy (semaglutide 2.4 mg), which falls within the plausible upper range of early-phase response seen in semaglutide trials, where rapid initial losses are partly driven by fluid shifts and acute appetite suppression. No dosing information, side effect disclosures, or lifestyle modification details are provided in the available content. Clinical evaluation by a licensed provider is necessary before starting or adjusting any GLP-1 receptor agonist regimen.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @alekosmos88's Wegovy progress claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@alekosmos88's Wegovy progress claim, fact-checked" from Alekosmos88. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports 8.

The reason this review is not generic is the source wording and the canonical claim label "glp1 tym razem waga drgn a mo e nie o tyle o ile tym chcia a a." In this clip, the useful excerpt is: "And then we had about fifteen years ago, we had everything to do from there, we had all the ability to go to a local program." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

8.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator reports 8.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator reports 8.1 kg of weight loss over five weeks on Wegovy (semaglutide 2.4 mg), which falls within the plausible upper range of early-phase response seen in semaglutide trials, where rapid initial losses are partly driven by fluid shifts and acute appetite suppression. No dosing information, side effect disclosures, or lifestyle modification details are provided in the available content. Clinical evaluation by a licensed provider is necessary before starting or adjusting any GLP-1 receptor agonist regimen.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, meaning early weeks often show faster losses than the overall average suggests.
  • 8.1 kg in 5 weeks is on the higher end of clinical expectations but is biologically plausible due to fluid shifts and rapid appetite suppression in the early treatment phase.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, meaning early weeks often show faster losses than the overall average suggests.
  • 8.1 kg in 5 weeks is on the higher end of clinical expectations but is biologically plausible due to fluid shifts and rapid appetite suppression in the early treatment phase.
  • Real-world semaglutide analysis (Rubino et al., 2023, Obesity) found that losing more than 5% in the first 12 weeks is associated with significantly better long-term outcomes.
  • Semaglutide is not a permanent fix: Rubino et al. (2022, Diabetes, Obesity and Metabolism) found patients regained roughly two-thirds of lost weight within one year of stopping treatment.
  • Compounded semaglutide is not equivalent to FDA-approved Wegovy. The FDA has issued safety alerts about compounded versions, and patients should confirm their prescription is for a licensed, approved product.
  • Side effects including nausea, fatigue, and GI distress are common in early weeks of treatment, particularly during dose escalation, and are not mentioned in this video despite being relevant for new users.
  • No TikTok weight-loss result, however honest in tone, substitutes for evaluation by a licensed provider who can assess whether semaglutide is appropriate for your specific health profile.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @alekosmos88 actually say?

The caption is doing more work than the transcript here. The spoken audio is garbled beyond any usable content, likely a transcription artifact. So we're working from what the creator wrote: after five weeks on Wegovy, they're down 8.1 kilograms. They acknowledge it's not as fast as they'd hoped, but the scale is moving down. That's the core claim.

To be clear about what we're fact-checking: this is a personal progress report, not a medical claim. The creator isn't promising Wegovy will work for everyone, isn't naming a dose, and isn't selling anything. They're sharing a number on a scale. That framing matters when we assess accuracy.

The caption's tone is honest in a useful way. "Może nie o tyle o ile tym chciała" translates roughly to "maybe not as much as I wanted." That kind of tempered expectation is actually more responsible than a lot of weight-loss content on this platform.

Does the science back this up?

An 8.1 kg loss in five weeks is on the higher end of what clinical data would predict, but it's not outside the range of real-world outcomes. It's worth unpacking why.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults on semaglutide 2.4 mg weekly for 68 weeks. Mean weight loss was 14.9% of body weight. That averages out to roughly 1–2 kg per week early in treatment, when water weight and rapid metabolic changes drive faster initial losses.

Week one through six on GLP-1 receptor agonists often produces disproportionately fast results. Semaglutide suppresses appetite rapidly, and early weight loss includes significant fluid shifts. So 8.1 kg across five weeks, while faster than the trial average, is biologically plausible, especially for someone with a higher starting weight.

A 2023 real-world analysis (Rubino et al., Obesity, 2023) found that early responders to semaglutide, defined as losing more than 5% in the first 12 weeks, had significantly better long-term outcomes. So if this creator's numbers hold, that could be a meaningful clinical signal, not just a good week.

What did they get wrong (or right)?

Honestly? They got the framing right. There are no miracle claims here, no promises, no before-and-after manipulation. They got something wrong only by omission, which is common in short-form content rather than intentional deception.

What's missing: context about what else is driving the loss. Wegovy doesn't work in a vacuum. The STEP trials combined semaglutide with lifestyle intervention. If the creator changed their diet or activity level alongside starting the medication, that's contributing to the 8.1 kg. The number is real, but the attribution may be incomplete.

There's also no mention of side effects. Nausea, fatigue, and GI distress are common in early weeks of semaglutide treatment, particularly during dose escalation. That's not a criticism of this creator specifically, but 22,000 viewers deserve to know that a fast start sometimes comes with a rough adjustment period.

The hashtag "dieta" (diet) alongside "wegovy" at least implies food changes are in the picture. That's more honest than some creators who imply the medication alone is responsible for everything.

What should you actually know?

If you're considering Wegovy, or already on it, here's what this video doesn't tell you.

  • Early weight loss on semaglutide is often faster than sustained loss. Weeks two through eight can look dramatic. The rate typically slows after the first couple of months as the body adjusts.
  • Semaglutide is a prescription medication approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It is not appropriate for everyone.
  • The drug works best alongside dietary changes and increased physical activity. It is not a replacement for those behaviors, it makes them easier to sustain by reducing hunger signals.
  • Stopping semaglutide abruptly is associated with weight regain. Rubino et al. (2022, Diabetes, Obesity and Metabolism) found participants regained about two-thirds of lost weight within a year of stopping. This is a long-term treatment for most people, not a short course.
  • Compounded semaglutide is not the same as brand-name Wegovy. The FDA has flagged safety concerns with compounded versions. If you're on Wegovy, make sure your prescription is for the actual approved product from a licensed pharmacy.

This creator's experience is real and relatable. But one person's five-week result is not a promise. Clinical outcomes vary based on starting weight, dose, adherence, and metabolic factors that no TikTok video can account for.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alekosmos88 · TikTok creator

22.1K views on this video

Tym razem waga drgnęła. Może nie o tyle o ile tym chciała, ale poszła w dół. Po 5 tygodniach na Wegovy mam na minusie 8,1 kg 💪🏻💪🏻💪🏻 Powoli idę do przodu. 🩷🩷🩷 #redukcja #wegovy #dieta #motywa

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, meaning early weeks often show faster losses than the overall average suggests.

What does the video say about 8.1 kg in 5 weeks?

8.1 kg in 5 weeks is on the higher end of clinical expectations but is biologically plausible due to fluid shifts and rapid appetite suppression in the early treatment phase.

What does the video say about real-world semaglutide analysis (rubino et al., 2023, obesity) found?

Real-world semaglutide analysis (Rubino et al., 2023, Obesity) found that losing more than 5% in the first 12 weeks is associated with significantly better long-term outcomes.

What does the video say about semaglutide?

Semaglutide is not a permanent fix: Rubino et al. (2022, Diabetes, Obesity and Metabolism) found patients regained roughly two-thirds of lost weight within one year of stopping treatment.

What does the video say about compounded semaglutide?

Compounded semaglutide is not equivalent to FDA-approved Wegovy. The FDA has issued safety alerts about compounded versions, and patients should confirm their prescription is for a licensed, approved product.

What does the video say about side effects including nausea, fatigue,?

Side effects including nausea, fatigue, and GI distress are common in early weeks of treatment, particularly during dose escalation, and are not mentioned in this video despite being relevant for new users.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alekosmos88, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.